Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EBV-specific immune effector cells
- Development stage
- Phase 2
- Lead developer
- Vectorite Biomedical
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
EBV-specific immune effector cells is an adoptive cell therapy developed by Vectorite Biomedica for the treatment and prevention of Epstein-Barr virus (EBV)-associated lymphoproliferative disorders. The therapy consists of autologous or donor-derived CD4+ and CD8+ T cells that are expanded ex vivo using a protein-spanning pool of pentadecapeptides derived from the EBV latent membrane protein 2A (LMP2A). These cells are selected based on activation markers such as IFN-γ or CD137 and stimulated with dendritic cells to enhance their specificity and potency. Once infused, these effector cells target and eliminate EBV-infected cells expressing viral antigens, particularly in the context of post-transplant lymphoproliferative disorder (PTLD).
- Other names
- EBV-specific T cellsEBV-specific CD4+ and CD8+ T cells
02
Targets
Epstein–Barr virus latent membrane protein 2A peptide-HLA class I complex
Beyond the preview
Go deeper on EBV-specific immune effector cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EBV-specific immune effector cells.